Erratum to Modulating endothelial nitric oxide synthase: A new cardiovascular therapeutic strategy (Am J Physiol Heart Circ Physiol, (2011), 301, (H634-H646), 10.1152/ajpheart.01315.2010);Modulating endothelial nitric oxide synthase: A new cardiovascular therapeutic strategy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 3, 2011, Pages

  Zhang, Yixuan ^a   Janssens, Stefan P ^b   Wingler, Kirstin ^a   Schmidt, Harald H H W ^a   Moens, An L ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Endothelial nitric oxide synthase uncoupling; Enhancers; Modulators; Nitric oxide donors; Superoxide; Tetrahydrobiopterin

Indexed keywords

2,2 DIFLUORO BENZO[1, 3]DIOXOLE 5 CARBOXYLIC ACID INDAN 2 YL AMIDE; 4 FLUORO N INDAN 2 YL BENZAMIDE; 5 METHYLTETRAHYDROFOLIC ACID; ARGININE; CARDIOVASCULAR AGENT; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; NETRIN 1; NITRIC OXIDE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; DRUG DOSE ESCALATION; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC MODEL; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION INITIATION; VASODILATATION;

EID: 80051944931     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.zh4-0471-corr.2012     Document Type: Erratum

References (167)

1. Aigrain L, Pompon D, Truan G. Role of the interface between the FMN and FAD domains in the control of redox potential and electronic transfer of NADPH-cytochrome P450 reductase. Biochem J 435: 197-206, 2011.
2. Al-Zobaidy MJ, Craig J, Martin W. Differential sensitivity of basal and acetylcholine-induced activity of nitric oxide to blockade by asymmetric dimethylarginine in the rat aorta. Br J Pharmacol 160: 1476-1483, 2010.
3. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, Diesch J, Tousoulis D, Stefanadis C, Leeson P. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 116: 2851-2859, 2007.
4. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 30: 1142-1150, 2009.
5. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114: 1193-1201, 2006.
6. Aoki C, Nakano A, Tanaka S, Yanagi K, Ohta S, Jojima T, Kasai K, Takekawa H, Hirata K, Hattori Y. Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells. Int J Cardiol 2010 Nov 17. [Epub ahead of print]
7. Bendall J, Alp N, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon K. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 97: 864-871, 2005.
8. Berbee M, Fu Q, Boerma M, Pathak R, Zhou D, Kumar K, Hauer-Jensen M. Reduction of radiation-induced vascular nitrosative stress by the vitamin E Analog γ-tocotrienol: evidence of a role for tetrahydrobiopterin. Int J Radiat Oncol Bio Phys 79: 884-891, 2010.
9. Berka V, Wu G, Yeh HC, Palmer G, Tsai AL. Three different oxygen-induced radical species in endothelial nitric-oxide synthase oxygenase domain under regulation by L-arginine and tetrahydrobiopterin. J Biol Chem 279: 32243-32251, 2004.
10. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
11. Bevers L, Braam B, Post J, van Zonneveld A, Rabelink T, Koomans H, Verhaar M, Joles J. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 47: 87-94, 2006.
12. Bloch KD, Janssens S. Cardiomyocyte-specific overexpression of nitric oxide synthase 3: impact on left ventricular function and myocardial infarction. Trends Cardiovasc Med 15: 249-253, 2005.
13. Boger RH. The pharmacodynamics of L-arginine. J Nutr 137: 1650S-1655S, 2007.
14. Boger RH, Tsikas D, Bode-Boger SM, Phivthong-Ngam L, Schwedhelm E, Frolich JC. Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-(15)N(2)]-arginine to (15)N-labeled nitrate by gas chromatography-mass spectrometry. Nitric Oxide 11: 1-8, 2004.
15. Bonaa K, Njolstad I, Ueland P, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug J, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588, 2006.
16. 2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem 276: 32663-32669, 2001.
17. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T, Maloney RE, Bharti A, Rodriguez J, Feelisch M. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 1: 290-297, 2005.
18. Burner U, Furtmüller PG, Kettle AJ, Koppenol WH, Obinger C. Mechanism of reaction of myeloperoxidase with nitrite. J Biol Chem 275: 20597-20601, 2000.
19. Calvert JW, Lefer DJ. Clinical translation of nitrite therapy for cardiovascular diseases. Nitric Oxide 22: 91-97, 2010.
20. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282: 879-887, 2007.
21. Castets M, Mehlen P. Netrin-1 role in angiogenesis: to be or not to be a pro-angiogenic factor? Cell Cycle 9: 1466-1471, 2010.
22. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468: 1115-1118, 2010.
23. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 88: 51-57, 2010.
24. Chen W, Druhan LJ, Chen CA, Hemann C, Chen YR, Berka V, Tsai AL, Zweier JL. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial nitric oxide synthase: transition from reversible to irreversible enzyme inhibition. Biochemistry 49: 3129-3137, 2010.
25. Chen YR. Involvement of protein radical, protein aggregation, and effects on NO metabolism in the hypochlorite-mediated oxidation of mitochondrial cytochrome c. Free Radic Biol Med 37: 1591-1603, 2004.
26. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9: 1498-1505, 2003.
27. Cosentino F, Patton S. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 101: 1530-1537, 1998.
28. Crabtree MJ, Tatham AL, Al-Wakeel Y, Warrick N, Hale AB, Cai S, Channon KM, Alp NJ. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterineNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 284: 1136-1144, 2009.
29. Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling. J Biol Chem 284: 28128-28163, 2009.
30. Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 96: 1872-1877, 2010.
31. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Longterm vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 92: 88-95, 2003.
32. De Castro S, Leung K, Savery D, Burren K, Rozen R, Copp A, Greene N. Neural tube defects induced by folate deficiency in mutant curly tail (Grhl3) embryos are associated with alteration in folate one carbon metabolism but are unlikely to result from diminished methylation. Birth Defects Res A Clin Mol Teratol 88: 612-618, 2010.
33. Dedio J, Konig P, Wohlfart P, Schroeder C, Kummer W, Muller-Esterl W. NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J 15: 79-89, 2001.
34. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry 47: 7256-7263, 2008.
35. Dumitrescu C, Biondi R, Xia Y, Cardounel AJ, Druhan LJ, Ambrosio G, Zweier JL. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci USA 104: 15081-15086, 2007.
36. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 121: 231-243, 1996.
37. Erwin PA, Lin AJ, Golan DE, Michel T. Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 280: 19888-19894, 2005.
38. Feron O, Balligand J. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69: 788-797, 2006.
39. Feron O, Dessy C, Moniotte S, Desager J, Balligand J. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 103: 897-905, 1999.
40. Fiorucci S, Santucci L, Gresele P, Faccino RM, del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124: 600-607, 2003.
41. Fraccarollo D, Widder J, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118: 818-827, 2008.
42. Frank P, Lee H, Park D, Tandon N, Scherer P, Lisanti M. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 24: 98-105, 2004.
43. Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder J, Dienesch C, Schäfer A, Podolskaya A, Held M, Ruetten H. The eNOSenhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 104: 773-779, 2009.
44. Fujimoto T. Calcium pump of the plasma membrane is localized in caveolae. J Cell Biol 120: 1147-1157, 1993.
45. Fulton D, Gratton J, Sessa W. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818-824, 2001.
46. Gao YT, Roman LJ, Martasek P, Panda SP, Ishimura Y, Masters BS. Oxygen metabolism by endothelial nitric-oxide synthase. J Biol Chem 282: 28557-28565, 2007.
47. Ghosh S, Gachhui R, Crooks C, Wu C, Lisanti M, Stuehr D. Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase. J Biol Chem 273: 22267-22271, 1998.
48. Godecke A, Decking UK, Ding Z, Hirchenhain J, Bidmon HJ, Godecke S, Schrader J. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res 82: 186-194, 1998.
49. Gonzalez E, Nagiel A, Lin A, Golan D, Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem 279: 40659-40669, 2004.
50. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 106: 2404-2408, 2002.
51. Hasegawa H, Sawabe K, Nakanishi N, Wakasugi OK. Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4. Mol Genet Metab 86, Suppl 1: S2-S10, 2005.
52. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner E. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276: 40-47, 2001.
53. Henning S, Swendseid M, Ivandic B, Liao F. Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. Free Radic Biol Med 23: 936-942, 1997.
54. Huang HS, Ma MC, Chen J. Chronic L-arginine administration increases oxidative and nitrosative stress in rat hyperoxaluric kidneys and excessive crystal deposition. Am J Physiol Renal Physiol 295: F388-F396, 2008.
55. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242, 1995.
56. Hyndman M, Verma S, Rosenfeld R, Anderson T, Parsons H. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 282: H2167-H2172, 2002.
57. Institute of Medicine, Food, and Nutrition Board. Dietary Reference Intake: Folate. Washington, DC: National Academy Press, 1998.
58. ISIS-4-Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 345: 669-685, 1995.
59. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94: 1256-1262, 2004.
60. Jayachandran M, Hayashi T, Sumi D, Iguchi A, Miller V. Temporal effects of 17β-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327-H1333, 2001.
61. Kapil V, Webb A, Ahluwalia A. Inorganic nitrate and the cardiovascular system. Heart 96: 1703-1709, 2010.
62. Katusic ZS, d'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 30: 48-54, 2009.
63. Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, Mayer B. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an SDS-resistant dimer. EMBO J 14: 3687-3695, 1995.
64. Klemenska E, Bersewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol J 16: 11-19, 2008.
65. Kotsonis P, Frohlich LG, Shutenko ZV, Horejsi R, Pfleiderer W, Schmidt HH. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem J 346: 767-776, 2000.
66. Kunuthur S, Milliken P, Gibson C, Suckling C, Wadsworth R. Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties. Eur J Pharmacol 650: 371-377, 2010.
67. Kuzkaya N, Weissmann N, Harrison D, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols. J Biol Chem 278: 22546-22554, 2003.
68. Landmesser U, Dikalov S, Price S, McCann L, Fukai T, Holland S, Mitch W, Harrison D. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
69. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 25: 1332-1340, 2005.
70. Li H, Forstermann U. Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des 15: 3133-3145, 2009.
71. Li H, Kundu TK, Zweier JL. Characterization of the magnitude and mechanism of aldehyde oxidase-mediated nitric oxide production from nitrite. J Biol Chem 284: 33850-33858, 2009.
72. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 42: 1150-1159, 2003.
73. List BM, Klosch B, Volker C, Gorren AC, Sessa WC, Werner ER, Kukovetz WR, Schmidt K, Mayer B. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem J 323: 159-165, 1997.
74. Liu X, Huang Y, Pokreisz P, Vermeersch P, Marsboom G, Swinnen M, Verbeken E, Santos J, Pellens M, Gillijns H, Van de Werf F, Bloch KD, Janssens S. Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. J Am Coll Cardiol 50: 808-817, 2007.
75. Lonn E, Yusuf S, Arnold M, Sheridan P, Pogue J, Micks M, McQueen M, Probstfield J, Fodor G, Held C. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006.
76. Loscalzo J. Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. Circulation 104: 1086-1088, 2001.
77. Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, Vinet L, Charue D, Vaudin E, Zhang W, Sainte-Marie Y, Robidel E, Marty I, Mayer B, Jaisser F, Mercadier JJ, Richard S, Shah AM, Benitah JP, Samuel JL, Heymes C. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 117: 3187-3198, 2008.
78. Lu X, Guo X, Wassall CD, Kemple MD, Unthank JL, Kassab GS. Reactive oxygen species cause endothelial dysfunction in chronic flowoverload. J Appl Physiol 110: 520-527, 2011.
79. Maia LB, Moura JJ. Nitrite reduction by xanthine oxidase family enzymes: a new class of nitrite reductases. J Biol Inorg Chem 16: 443-460, 2011.
80. Maniatis NA, Brovkovych V, Allen SE, John TA, Shajahan AN, Tiruppathi C, Vogel SM, Skidgel RA, Malik AB, Minshall RD. Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ Res 99: 870-877, 2006.
81. Mata-Greenwood E, Jenkins C, Farrow KN, Konduri GG, Russell JA, Lakshminrusimha S, Black SM, Steinhorn RH. eNOS function is developmentally regulated: uncoupling of eNOS occurs postnatally. Am J Physiol Lung Cell Mol Physiol 290: L232-L241, 2006.
82. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 272: 31213-31216, 1997.
83. Mehlen P, Guenebeaud C. Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol 22: 46-54, 2010.
84. Mehlen P, Rama N. Netrin-1 and axonal guidance: signaling and asymmetrical translation. [French.] Med Sci (Paris) 23: 311-315, 2007.
85. 2+-calmodulin and caveolin. J Biol Chem 272: 15583-15586, 1997.
86. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 356: 1464-1469, 2000.
87. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263: 681-684, 1999.
88. Minshall R, Sessa W, Stan R, Anderson R, Malik A. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 285: L1179-L1183, 2003.
89. Moens A, Champion H, Claeys M, Tavazzi B, Kaminski P, Wolin M, Borgonjon D, Van Nassauw L, Haile A, Zviman M. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 117: 1810-1819, 2008.
90. Moens A, Kass D. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol 50: 238-246, 2007.
91. Moens A, Takimoto E, Tocchetti C, Chakir K, Bedja D, Cormaci G, Ketner E, Majmudar M, Gabrielson K, Halushka M. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117: 2626-2636, 2008.
92. Moens A, Vrints C, Claeys M, Timmermans J, Champion H, Kass D. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol 294: H1971-H1977, 2008.
93. Monti M, Donnini S, Giachetti A, Mochly-Rosen D, Ziche M. δ-PKC inhibition or PKC activation repairs endothelial vascular dysfunction by regulating eNOS post-translational modification. J Mol Cell Cardiol 48: 746-756, 2010.
94. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42: 271-279, 2007.
95. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, Schulz R, Butany J, Stewart DJ, Husain M. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109: 735-743, 2002.
96. Nagasaka Y, Fernandez BO, Garcia-Saura MF, Petersen B, Ichinose F, Bloch KD, Feelisch M, Zapol WM. Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology 109: 675-682, 2008.
97. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K, Yatera Y, Sabanai K, Tanimoto A, Nagasaki M, Tasaki H, Sasaguri Y, Nakashima Y, Otsuji Y, Yanagihara N. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117: 2211-2223, 2008.
98. Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev 18: 190-197, 2010.
99. Nossuli TO, Hayward R, Jensen D, Scalia R, Lefer AM. Mechanisms of cardioprotection by peroxynitrite in myocardial ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol 275: H509-H519, 1998.
100. O'Connor DM, O'Brien T. Nitric oxide synthase gene therapy: progress and prospects. Expert Opin Biol Ther 9: 867-878, 2009.
101. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 102: 2061-2071, 1998.
102. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110: 331-340, 2002.
103. Pant K, Crane BR. Structure of a loose dimer: an intermediate in nitric oxide synthase assembly. J Mol Biol 352: 932-940, 2005.
104. Parry TE. Folate responsive neuropathy. Presse Med 23: 131-137, 1994.
105. Peterson TE, d'Uscio LV, Cao S, Wang XL, Katusic ZS. Guanosine triphosphate cyclohydrolase I expression and enzymatic activity are present in caveolae of endothelial cells. Hypertension 53: 189-195, 2009.
106. Qipshidze N, Tyagi N, Sen U, Givvimani S, Metreveli N, Lominadze D, Tyagi S. Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes post-MI. Am J Physiol Heart Circ Physiol 299: H1484-H1493, 2010.
107. Razani B, Engelman J, Wang X, Schubert W, Zhang X, Marks C, Macaluso F, Russell R, Li M, Pestell R. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
108. Reif A, Frohlich LG, Kotsonis P, Frey A, Bommel HM, Wink DA, Pfleiderer W, Schmidt HH. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem 274: 24921-24929, 1999.
109. Riad A, Westermann D, Van Linthout S, Mohr Z, Uyulmaz S, Becher P, Rütten H, Wohlfart P, Peters H, Schultheiss H. Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia 51: 2325-2332, 2008.
110. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, Rossig L, Koehl U, Koyanagi M, Mohamed A. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103: 14537-14541, 2006.
111. Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 14: 835-846, 2005.
112. Schafer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail 11: 336-341, 2009.
113. Schilling K, Opitz N, Wiesenthal A, Oess S, Tikkanen R, Muller-Esterl W, Icking A. Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 and NOSTRIN. Mol Biol Cell 17: 3870-3880, 2006.
114. Schmidt HH, Nau H, Wittfoht W, Gerlach J, Prescher KE, Klein MM, Niroomand F, Bohme E. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 154: 213-216, 1988.
115. Schmidt T, McNeill E, Douglas G, Crabtree M, Hale A, Khoo J, O'Neill C, Cheng A, Channon K, Alp N. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein E-knockout mice. Clin Sci (Lond) 119: 131-142, 2010.
116. Schuhmacher S, Schulz E, Oelze M, Konig A, Roegler C, Lange K, Sydow L, Kawamoto T, Wenzel P, Munzel T, Lehmann J, Daiber A. A new class of organic nitrates: investigations on bioactivation, tolerance and cross-tolerance phenomena. Br J Pharmacol 158: 510-520, 2009.
117. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295: 58-64, 2006.
118. Seerapu H, Subramaniam G, Majumder S, Sinha S, Bisana S, Mahajan S, Kolluru G, Muley A, Siamwala J. Inhibition of dynamin-2 confers endothelial barrier dysfunctions by attenuating nitric oxide production. Cell Biol Int 34: 755-761, 2010.
119. Selemidis S. Suppressing NADPH oxidase-dependent oxidative stress in the vasculature with nitric oxide donors. Clin Exp Pharmacol Physiol 35: 1395-1401, 2008.
120. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 93: 13176-13181, 1996.
121. Shimokawa H, Tsutsui M. Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice. Pflügers Arch 459: 959-967, 2010.
122. Shiva S, Rassaf T, Patel RP, Gladwin MT. The detection of the nitrite reductase and NO-generating properties of haemoglobin by mitochondrial inhibition. Cardiovasc Res 89: 566-573, 2011.
123. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, Miyajima H, Hogg N, Harris ZL, Gladwin MT. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2: 486-493, 2006.
124. Simon A, Plies L, Habermeier A, Martine U, Reining M, Closs EI. Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ Res 93: 813-820, 2003.
125. Sowa G, Pypaert M, Sessa W. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc Natl Acad Sci USA 98: 14072-14077, 2001.
126. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab 3: 211-223, 2002.
127. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother 9: 1393-1412, 2009.
128. Stoll S, NejatyJahromy Y, Woodward J, Ozarowski A, Marletta M, Britt R. Nitric oxide synthase stabilizes the tetrahydrobiopterin cofactor radical by controlling its protonation state. J Am Chem Soc 132: 11812-23, 2010.
129. Suckling CJ, Gibson CL, Huggan JK, Morthala RR, Clarke B, Kununthur S, Wadsworth RM, Daff S, Papale D. 6-Acetyl-7,7-dimethyl-5,6,7,8-tetrahydropterin is an activator of nitric oxide synthases. Bioorg Med Chem Lett 18: 1563-1566, 2008.
130. Sud N, Wiseman D, Black S. Caveolin 1 is required for the activation of endothelial nitric oxide synthase in response to 17β-estradiol. Mol Endocrinol 24: 1637-1649, 2010.
131. Suh J, Choi D, Chang H, Cho Y, Youn T, Chae I, Kim K, Kim C, Kim H, Oh B. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Korean Med Sci 25: 16-23, 2010.
132. Sun J, Murphy E. Protein S-nitrosylation and cardioprotection. Circ Res 106: 285-296, 2010.
133. Takimoto E, Champion H, Li M, Ren S, Rodriguez E, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson K, Wang Y. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231, 2005.
134. Tayeh M, Marletta M. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 264: 19654-19658, 1989.
135. Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder JD, Tsikas D, Ertl G, Bauersachs J. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56: 666-674, 2007.
136. Tian J, Hou Y, Lu Q, Wiseman D, Vasconcelos Fonsesca F, Elms S, Fulton D, Black S. A novel role for caveolin-1 in regulating endothelial nitric oxide synthase activation in response to H2O2 and shear stress. Free Radic Biol Med 49: 159-170, 2010.
137. Tian R, Ingwall J. How does folic acid cure heart attacks? Circulation 117: 1772-1774, 2008.
138. Tiefenbacher CP, Chilian WM, Mitchell M, DeFily DV. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. Circulation 94: 1423-1429, 1996.
139. Tiravanti E, Samouilov A, Zweier JL. Nitrosyl-heme complexes are formed in the ischemic heart: evidence of nitrite-derived nitric oxide formation, storage, and signaling in post-ischemic tissues. J Biol Chem 279: 11065-11073, 2004.
140. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, Frizzell S, Jayaraman T, Geary L, Shapiro C. Human neuroglobin functions as a redox regulated nitrite reductase. J Biol Chem 286: 18277-18289, 2011.
141. Valleggi S, Devaraj S, Dasu M, Jialal I. C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase. Clin Chem 56: 1345-1348, 2010.
142. van Etten R, de Koning E, Verhaar M, Gaillard C, Rabelink T. Impaired NO-dependent vasodilation in patients with Type II (noninsulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45: 1004-1010, 2002.
143. van Haperen R, de Waard M, van Deel E, Mees B, Kutryk M, van Aken T, Hamming J, Grosveld F, Duncker DJ, de Crom R. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 277: 48803-48807, 2002.
144. Vásquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 22: 1655-1661, 2002.
145. Vásquez-Vivar J, Martásek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 362: 733-739, 2002.
146. Verhaar M, Wever R, Kastelein J, van Dam T, Koomans H, Rabelink T. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97: 237-241, 1998.
147. Walter R, Schaffner A, Blau N, Kierat L, Schoedon G. Tetrahydrobiopterin is a secretory product of murine vascular endothelial cells. Biochem Biophys Res Commun 203: 1522-1526, 1994.
148. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007, 2005.
149. Westermann D, Riad A, Richter U, Jäger S, Savvatis K, Schuchardt M, Bergmann N, Tölle M, Nagorsen D, Gotthardt M. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol 104: 499-509, 2009.
150. Williams T, Lisanti M. The Caveolin genes: from cell biology to medicine. Ann Med 36: 584-595, 2004.
151. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116: 188-195, 2007.
152. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs E, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 325: 370-379, 2008.
153. Woo K, Chook P, Lolin Y, Sanderson J, Metreweli C, Celermajer D. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 34: 2002-2006, 1999.
154. Woodman S, Park D, Cohen A, Cheung M, Chandra M, Shirani J, Tang B, Jelicks L, Kitsis R, Christ G. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277: 38988-38997, 2002.
155. Xia W, Low P. Folate-targeted therapies for cancer. J Med Chem 53: 66-76, 2010.
156. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 93: 6770-6774, 1996.
157. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273: 25804-25808, 1998.
158. Xue H, He G, Huang J, Yang Q. New strategy of endothelial protection in cardiac surgery: use of enhancer of endothelial nitric oxide synthase. World J Surg 34: 1461-1469, 2010.
159. Xue H, He G, Wong W, Tian X, Underwood M, Huang Y, Yang Q. Treatment of endothelial dysfunction in hypertension: the role of enhancement of eNOS expression. FASEB J 23: 1017-1021, 2009.
160. Yamashiro S, Noguchi K, Kuniyoshi Y, Koja K, Sakanashi M. Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Card Surg 44: 37-49, 2003.
161. Zhang J, Cai H. netrin-1 prevents ischemia/reperfusion-induced myocardial infarction via a DCC/ERK1/2/eNOS (s1177)/NO/DCC feedforward mechanism. J Mol Cell Cardiol 48: 1060-1070, 2010.
162. Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar S, Bao X, Rana B, Smith D, Wessel J. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 117: 2658-2671, 2007.
163. Zhao Y, Liu Y, Stan R, Fan L, Gu Y, Dalton N, Chu P, Peterson K, Ross J, Chien K. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380, 2002.
164. Zhao Y, Zhao Y, Mirza M, Huang J, Potula H, Vogel S, Brovkovych V, Yuan J, Wharton J, Malik A. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 119, 2009-2018, 2009.
165. Zimmermann K, Opitz N, Dedio J, Renné C, Müller-Esterl W, Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 99: 17167-17172, 2002.
166. Zweier JL, Li H, Samouilov A, Liu X. Mechanisms of nitrite reduction to nitric oxide in the heart and vessel wall. Nitric Oxide 22: 83-90, 2010.
167. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1: 804-809, 1995.